Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMISOL: DT-7012 in Advanced Solid Tumors
NCT06819735Phase 2Recruiting
- Sponsor
- Domain Therapeutics
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of DT-7012 in solid tumor, sponsored by Domain Therapeutics. Started Jun 2025; status: recruiting.
02
Drugs
DT-7012
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06819735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819735.